[Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000009:adverse effects / Q000627:therapeutic use*; D019233:Retreatment; D013449:Sulfonamides; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir